Clinical Trial: A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07714668) titled 'A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer' on July 08.

Brief Summary: This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer Recurrent Ovarian Cancer

Intervention: DRUG: SYS6041, bevacizumab

SYS6041: RP2D dose, ivgtt, Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W

DRUG: SYS6041, carboplatin, bevacizumab

SYS6041: RP2D dose, ivgtt, Q3W Carboplatin: AUC5, ivgtt. Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W

DRUG: paclitaxel, carboplatin, bevacizumab

Paclitaxel:175mg/m2, ivgtt...